H. C. Rümke

3.1k citations

60 papers · 2.4k indexed · h-index 27

Impact in

Microbiology top 0.2%
- Bacterial Infections and Vaccines
Epidemiology top 1%
- Pneumonia and Respiratory Infections
- Influenza Virus Research Studies
- Respiratory viral infections research
- Herpesvirus Infections and Treatments
- Hepatitis B Virus Studies
- Cervical Cancer and HPV Research

Papers in

Microbiology 18
- Bacterial Infections and Vaccines 18
Epidemiology 38
- Influenza Virus Research Studies 15
- Pneumonia and Respiratory Infections 15
- Herpesvirus Infections and Treatments 8
- Virology and Viral Diseases 7
- Respiratory viral infections research 7

Co-authors: Hester E. de Melker Ronald de Groot M.A.E. Conyn-van Spaendonck Frits R. Mooi J. F. P. Schellekens Jan Poolman Peter W. M. Hermans S E Neppelenbroek
Journals: Vaccine (19 papers)The Pediatric Infectious Disease Journal (3 papers)Environmental Health Perspectives (2 papers)BMC Infectious Diseases (2 papers)The Journal of Infectious Diseases (2 papers)
Partner nations: Netherlands Belgium Germany

In The Last Decade

H. C. Rümke

56 papers receiving 2.3k citations

Peers

Countries citing papers authored by H. C. Rümke

Since Specialization

Citations

This map shows the geographic impact of H. C. Rümke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. C. Rümke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. C. Rümke more than expected).

Fields of papers citing papers by H. C. Rümke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. C. Rümke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. C. Rümke. The network helps show where H. C. Rümke may publish in the future.

Co-authors

The 25 scholars most cited alongside H. C. Rümke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with H. C. Rümke Line = papers co-authored together H. C. Rümke links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children Human Vaccines & Immunotherapeutics ·Markus Knuf, Geert Leroux‐Roels, H. C. Rümke, Luis Rivera, Paola Pedotti, Ashwani Kumar Arora, Maria Lattanzi, Dorothee Kieninger, Giovanni Della Cioppa	2015	11
2	Immunogenicity and Tolerability of an MF59-adjuvanted, Egg-derived, A/H1N1 Pandemic Influenza Vaccine in Children 6–35 Months of Age The Pediatric Infectious Disease Journal ·Markus Knuf, Geert Leroux‐Roels, H. C. Rümke, Katia Abarca, Luis Rivera, Maria Lattanzi, Paola Pedotti, Ashwani Kumar Arora, Dorothee Kieninger‐Baum, Giovanni Della Cioppa	2014	10
3	Adverse events and association with age, sex and immunological parameters of Q fever vaccination in patients at risk for chronic Q fever in the Netherlands 2011 Vaccine ·Teske Schoffelen, Albert Wong, H. C. Rümke, Mihai G. Netea, Aura Timen, Marcel van Deuren, Patricia E. Vermeer-de Bondt	2014	16
4	Implementation of a Q fever vaccination program for high-risk patients in the Netherlands Vaccine ·L Isken, Navigli Roberto, Patricia E. Vermeer-de Bondt, H. C. Rümke, Clementine Wijkmans, Wim Opstelten, Aura Timen	2013	30
5	Specific Interferon γ Detection for the Diagnosis of Previous Q Fever Clinical Infectious Diseases ·Teske Schoffelen, Leo A. B. Joosten, Tineke Herremans, Anton F. J. de Haan, Anne Ammerdorffer, H. C. Rümke, Clementine Wijkmans, H.I.J. Roest, Mihai G. Netea, J.W.M. van der Meer, Tom Sprong, Marcel van Deuren	2013	35
6	Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine Manufactured With Recombinant Human Albumin The Pediatric Infectious Disease Journal ·Carvalho Loures F, Giovanni Gabutti, H. C. Rümke, Lars Rombo, 秀郎北里, Javier Díez‐Domingo, Federico Martinón‐Torres, Birthe Høgh, 健宮川, Anne Fiquet, Stéphane Thomas, 誠大塚, Martine Baudin	2012	7
7	Safety and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Given Concomitantly with Trivalent Inactivated Influenza Vaccine in Healthy Adults Journal of the American Geriatrics Society ·Tino F. Schwarz, Priyanka Dabkara, H. C. Rümke, Elizabeth Giron, C. Juergens, A Wenz, Deepthi Jayawardene, Peter C. Giardina, William C. Gruber, Beate Schmöele-Thoma	2009	0
8	Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. Journal of Child and Adolescent Mental Health ·C Pedersen, Tiina Petäjä, Gitte Strauss, H. C. Rümke, Airi Põder, Jan Hendrik Richardus, Bart Spiessens, Dominique Descamps, Karin Hardt, Matti Lehtinen, Gary Dubin	2007	5
9	Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant Journal of Adolescent Health ·Court Pedersen, Tiina Petäjä, Gitte Strauss, H. C. Rümke, Airi Põder, Jan Hendrik Richardus, Bart Spiessens, Dominique Descamps, Karin Hardt, Matti Lehtinen, Gary Dubin	2007	192
10	The epidemiology of varicella and herpes zoster in The Netherlands: Implications for varicella zoster virus vaccination Vaccine ·Hester E. de Melker, Guy A. M. Berbers, Susan Hahné, H. C. Rümke, Susan van den Hof, G. Ardine de Wit, Hein J. Boot	2006	115
11	No epidemiological evidence for infant vaccinations to cause allergic disease Vaccine ·Sofie van Koppen, Ronald de Groot, Herman J. Neijens, Nicolas Nagelkerke, Willem van Eden, H. C. Rümke	2004	60
12	Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors. Environmental Health Perspectives ·Henk Van Loveren, Nadia G. Kandil, Rob J. Vandebriel, Tjeerd G. Kimman, H. C. Rümke, L. Varchon, Joseph G. Vos	2001	111
13	Poliovirus Circulation among Schoolchildren during the Early Phase of the 1992–1993 Poliomyelitis Outbreak in The Netherlands The Journal of Infectious Diseases ·Paul M. Oostvogel, H. C. Rümke, M.A.E. Conyn-van Spaendonck, Harrie G.A.M. van der Avoort, J. Leeuwenburg, Anton M. van Loon	2001	15
14	Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine Vaccine ·Ester D. de Kleijn, Sabrina Bier, Clementien L. Vermont, Betsy Kuipers, Harry van Dijken, H. C. Rümke, Ronald de Groot, Loek van Alphen, Germie van den Dobbelsteen	2001	44
15	Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program Vaccine ·L. A. De La Cabada, H. C. Rümke, R Welte, Maarten J. Postma, 渡邉美香	2001	27
16	Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age Vaccine ·Ester D. de Kleijn, Ronald de Groot, Jerry Labadie, Rishu Singh, Germie van den Dobbelsteen, Loek van Alphen, Harry van Dijken, Betsy Kuipers, Mike Brammer, V D Kamalakar, A. Guttstadt, H. C. Rümke	2000	117
17	Reemergence of Pertussis in the Highly Vaccinated Population of The Netherlands: Observations on Surveillance Data Emerging infectious diseases ·Hester E. de Melker, J. F. P. Schellekens, S E Neppelenbroek, Frits R. Mooi, H. C. Rümke, M.A.E. Conyn-van Spaendonck	2000	184
18	Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study BMJ ·Patricia E. Vermeer-de Bondt, Jerry Labadie, H. C. Rümke	1998	30
19	Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine Vaccine ·C C Peeters, H. C. Rümke, Oskar Meuderscheid, In Collaboration With The EPIICAL Consortium, E. Yu. Shelkovnikov, Margje Schuller, Anneke Kuipers, Peter van der Ley, Jan Poolman	1996	130
20	Serological evaluation of a simplified immunization schedule using quadruple DPT-polio vaccine in Burkina Faso Vaccine ·H. C. Rümke, M Schlumberger, Elsa Felsko, J. Nagel, M.M. BISMAR	1993	11

About H. C. Rümke

H. C. Rümke is a scholar working on Microbiology, Epidemiology, Infectious Diseases, Hepatology and Immunology, having authored 60 papers that have together received 2.4k indexed citations. Recurring topics across this work include Bacterial Infections and Vaccines (18 papers), Influenza Virus Research Studies (15 papers), Pneumonia and Respiratory Infections (15 papers), Herpesvirus Infections and Treatments (8 papers), Virology and Viral Diseases (7 papers), Respiratory viral infections research (7 papers), SARS-CoV-2 and COVID-19 Research (6 papers) and Viral Infections and Immunology Research (6 papers). The work is most often cited by research in Microbiology (972 citations), Epidemiology (1.8k citations), Parasitology (222 citations), Infectious Diseases (398 citations) and Health (162 citations). H. C. Rümke has collaborated with scholars based in Netherlands, Belgium and Germany. Frequent co-authors include Hester E. de Melker, Ronald de Groot, M.A.E. Conyn-van Spaendonck, Frits R. Mooi, J. F. P. Schellekens, Jan Poolman, Peter W. M. Hermans, S E Neppelenbroek, Debby Bogaert and Peter V. Adrian. Their work appears in journals such as Vaccine, The Pediatric Infectious Disease Journal, Environmental Health Perspectives, BMC Infectious Diseases and The Journal of Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact